Speakers include Kevin Outterson, Executive Director of CARB-X.

The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development, regulatory, and market incentives proposals, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI.

This public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative, administrative, and private sector mechanisms.